Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TAP (Docetaxel, Doxorubicin, Prednisone) in Hormone-Refractory Prostate Cancer
NCT00416533Phase 2Completed
- Sponsor
- Wake Forest University Health Sciences
- Start
- Aug 2004
- Primary completion
- Oct 2006
- Modality
- DNA Intercalators/Alkylators
01
Overview
A Phase 2 trial of doxorubicin in prostate cancer (PCa), sponsored by Wake Forest University Health Sciences. Started Aug 2004; status: completed.
02
Drugs
doxorubicin
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NCT00416533.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00416533.